MDV Medivation

SAN FRANCISCO, Jan. 17 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) today announced that it has appointed Lisa Taylor as vice president of commercial development. Ms. Taylor is responsible for the Company's market research, market development, communications and pre-launch planning functions. "Lisa has a strong background in product commercialization and more than 20 years of experience in the pharmaceutical, biotech, medical device and diagnostics industries. Her addition to our senior management team comes at an important time as we advance our lead product candidate Dimebon(TM) through clinical development as a potential treatment for Alzheimer's and Huntington's diseases," said David Hung, M.D., president and chief executive officer of Medivation. For the past year, Ms. Taylor has served as a consultant to Medivation. She joins the Company from Packers Falls Group, Inc., a consultancy she founded and for which she has served as principal for more than a decade. There she assisted a number of companies, including Genentech and Johnson & Johnson, with opportunity assessment, market planning and strategic analysis. Earlier in her career, she held positions with Natus Medical Inc., Medasonics, Angenics, Inc., Ciba-Corning Diagnostics and Booz, Allen & Hamilton. Ms. Taylor earned an A.B. in Human Biology from Stanford University and an M.B.A. from Harvard Business School. About Medivation Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/ . This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005, and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2006, June 30, 2006, and September 30, 2006, include more information about factors that could affect the Company's financial and operating results. DATASOURCE: Medivation, Inc. CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners, +1-415-946-1064 Web site: http://www.medivation.com/

Copyright